Increasing Need for Immunotherapies and Stem Cell and Regenerative Medicines Presents Opportunities

company logo

Global Recombinant Cell Culture Supplements Market

Global Recombinant Cell Culture Supplements Market

DUBLIN, Sept. 05, 2022 (GLOBE NEWSWIRE) — The “Global Recombinant Cell Culture Supplements Market: Focus on Pricing Analysis, Product, Application, Expression System, and Region – Analysis and Forecast, 2022-2032” report has been added to ResearchAndMarkets.com’s offering.

The global recombinant cell culture supplements market was estimated at $308.6 million in 2021 and is expected to reach $1,188.6 million by 2032, growing at a CAGR value of 12.24% during the forecast period 2022-2032. The growth in the global recombinant cell culture supplements market is expected to be driven by the rising demand for cell culture supplements, increasing investment in life sciences research and development, as well as growing advantages of recombinant supplements over traditional animal-derived supplements.

Market Lifecycle Stage

The global recombinant cell culture market is increasing at a rapid pace. The growing need for animal-free supplements in cell culture applications is aiding the growth of the recombinant cell culture supplements market. Recombinant cell culture supplements play a crucial role in enhancing cell viability, maintaining a healthy culture, and customizing the cell culture in accordance with the needs of the individual.

Increasing demand for immunotherapy and stem cell and regenerative medicine research is one of the major opportunities in the recombinant cell culture supplements market. Several cell culture companies, and biopharmaceutical companies are working collaboratively on drug development and using recombinant cell culture supplements as a therapeutic means for applications in biological drugs. Furthermore, the market witnessed major mergers and acquisitions in the past four years. For instance, recently, in March 2022, Thermo Fisher Scientific Inc. acquired PeproTech, Inc., a company that specializes in the development and manufacturing of recombinant proteins, in a deal of $1.85 billion.

Story continues

Impact

Many biopharmaceutical products are being developed by utilizing the cell culture technique. The study of cell physiology and biochemistry is made possible through laboratory cell culture, which also opens up research avenues that are challenging to pursue in vivo. Controlling variables such as the culture media, culture conditions, population density, and growth rate makes it simple to assess the effects of medications or other substances on cultured cells.

Additionally, it allows analyzing the function of various genes and offers enormous potential in the field of genetics. It enables the assessment of harmful and carcinogenic chemicals on cells in the fields of oncology and virology and the comprehension of how different medications, viruses, and physical or chemical carcinogens interact.

Furthermore, the recombinant cell culture has various applications, such as research on vaccines, stem cells, gene therapy, and genetic engineering, as well as the creation of protein therapies manufacturing of genetically edited proteins such as monoclonal antibodies, insulin, and hormones.

Market Dynamics

Market Drivers

  • Increasing Demand for Recombinant Cell Culture Supplements Due to their Advantages

  • Increased Funding and Investment in Research and Development for Biopharmaceutical Products in Life Sciences Sector

  • Growing Number of Mergers and Acquisitions for Expanding Recombinant Cell Culture Supplements Portfolio

  • Push from Regulatory Bodies to Utilize Animal-Free Media Supplements in Cell Culture Process

Market restraints

Market Opportunities

Market segmentation
by Product

  • Recombinant Albumin (rAlbumin)

  • Recombinant Insulin (rInsulin)

  • Recombinant Epidermal Growth Factor (rEGF)

  • Recombinant Interleukin Growth Factor (rILGF)

  • Recombinant Transferrin (rTransferrin)

  • Recombinant Trypsin (rTrypsin)

  • Recombinant Insulin-like Growth Factor (rIGF)

  • Recombinant Stem Cell Factor (rSCF)

  • Recombinant Aprotinin (rAprotinin)

  • Recombinant Lysozyme (rLysozyme)

  • Others

by application

by Expression System

  • mammalian

  • E.coli

  • yeast

  • Others

by region

  • NorthAmerica

  • Europe

  • Asia Pacific

  • Latin America

  • Rest of the World

Demand – Drivers and Limitations
The following are the demand drivers for the global recombinant cell culture supplements market:

  • Increasing Demand for Recombinant Cell Culture Supplements Due to their Advantages

  • Increased Funding and Investment in Research and Development for Biopharmaceutical Products in Life Sciences Sector

  • Growing Number of Mergers and Acquisitions for Expanding Recombinant Cell Culture Supplements Portfolio

  • Push from Regulatory Bodies to Utilize Animal-Free Media Supplements in Cell Culture Process

The market is expected to face some limitations too due to the following challenges:

Key topics covered:

1 Market Overview

2 Product, $Mn, 2021-2032

3 Application, $Mn, 2021-2032

4 Expression System, $Mn, 2021-2032

5 Region, $Mn, 2021-2032

6 Competitive Landscape

7 company profiles

Companies Mentioned

  • Abcam plc.

  • BBI Solutions

  • Corning Incorporated

  • FUJIFILM Irvine Scientific, Inc.

  • Gemini Bioproducts, LLC

  • HiMedia Laboratories

  • InVitria

  • Kingfisher Biotech, Inc.

  • Lonza Group Ltd

  • Merck KGaA

  • Novus Biologicals, LLC

  • R&D Systems, Inc.

  • Sartorius AG

  • Sino Biological Inc.

  • STEMCELL Technologies Inc.

  • Thermo Fisher Scientific Inc.

For more information about this report visit https://www.researchandmarkets.com/r/2s1ob7

attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For EST Office Hours Call 1-917-300-0470 For US/CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call + 353-1-416-8900